MX2020003388A - Composiciones y metodos para tratar cancer hepatico. - Google Patents

Composiciones y metodos para tratar cancer hepatico.

Info

Publication number
MX2020003388A
MX2020003388A MX2020003388A MX2020003388A MX2020003388A MX 2020003388 A MX2020003388 A MX 2020003388A MX 2020003388 A MX2020003388 A MX 2020003388A MX 2020003388 A MX2020003388 A MX 2020003388A MX 2020003388 A MX2020003388 A MX 2020003388A
Authority
MX
Mexico
Prior art keywords
compositions
methods
liver cancer
treating liver
pembrolizumab
Prior art date
Application number
MX2020003388A
Other languages
English (en)
Inventor
Jennifer Lorraine Gansert
Swaminathan Murugappan
Michael Kevin Wolf
Original Assignee
Merck Sharp & Dohme
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp & Dohme filed Critical Merck Sharp & Dohme
Publication of MX2020003388A publication Critical patent/MX2020003388A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/763—Herpes virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/844—Liver
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Endocrinology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Se proporcionan métodos y composiciones para tratar los cánceres hepáticos primarios y/o los cánceres hepáticos secundarios que usan una combinación de talimogene laherparepvec y pembrolizumab, una variante de pembrolizumab o un fragmento de unión a antígeno de los mismos.
MX2020003388A 2017-10-27 2018-10-26 Composiciones y metodos para tratar cancer hepatico. MX2020003388A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762578071P 2017-10-27 2017-10-27
PCT/US2018/057731 WO2019084418A1 (en) 2017-10-27 2018-10-26 COMPOSITIONS AND METHODS FOR THE TREATMENT OF LIVER CANCER

Publications (1)

Publication Number Publication Date
MX2020003388A true MX2020003388A (es) 2020-08-03

Family

ID=64453576

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020003388A MX2020003388A (es) 2017-10-27 2018-10-26 Composiciones y metodos para tratar cancer hepatico.

Country Status (13)

Country Link
US (1) US20200353022A1 (es)
EP (1) EP3700544A1 (es)
JP (1) JP2021501150A (es)
KR (1) KR20200078483A (es)
CN (1) CN111278448A (es)
AR (1) AR113805A1 (es)
AU (1) AU2018355519A1 (es)
BR (1) BR112020007494A2 (es)
CA (1) CA3075294A1 (es)
MX (1) MX2020003388A (es)
SG (1) SG11202002123XA (es)
TW (1) TWI817958B (es)
WO (1) WO2019084418A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3222634A1 (en) 2007-06-18 2017-09-27 Merck Sharp & Dohme B.V. Antibodies to human programmed death receptor pd-1
EP3615934A1 (en) * 2017-04-28 2020-03-04 Merck Sharp & Dohme Corp. Biomarkers for cancer therapeutics

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1252322B2 (en) 2000-01-21 2009-03-04 BioVex Limited Herpes virus strains for gene therapy
EP3222634A1 (en) 2007-06-18 2017-09-27 Merck Sharp & Dohme B.V. Antibodies to human programmed death receptor pd-1
EP2691112B1 (en) 2011-03-31 2018-05-23 Merck Sharp & Dohme Corp. Stable formulations of antibodies to human programmed death receptor pd-1 and related treatments
CN114984062A (zh) 2012-08-30 2022-09-02 安姆根有限公司 使用单纯疱疹病毒和免疫检查点抑制剂治疗黑色素瘤的方法
CA2955084C (en) * 2014-07-16 2023-08-29 Transgene Sa Combination of oncolytic virus with immune checkpoint modulators
PT3169341T (pt) * 2014-07-16 2019-09-09 Transgene Sa Vírus oncolítico para a expressão de moduladores de pontos de controlo imunitário
WO2016196173A1 (en) 2015-05-29 2016-12-08 Merck Sharp & Dohme Corp. Combination of a pd-1 antagonist and cpg-c type oligonucleotide for treating cancer
EP3426271A4 (en) * 2016-03-10 2019-10-16 Cold Genesys, Inc. METHODS OF TREATING SOLID OR LYMPHATIC TUMORS BY POLYTHERAPY
AU2017375958A1 (en) * 2016-12-12 2019-07-04 Multivir Inc. Methods and compositions comprising viral gene therapy and an immune checkpoint inhibitor for treatment and prevention of cancer and infectious diseases
EP3615934A1 (en) * 2017-04-28 2020-03-04 Merck Sharp & Dohme Corp. Biomarkers for cancer therapeutics

Also Published As

Publication number Publication date
TW201922273A (zh) 2019-06-16
AU2018355519A1 (en) 2020-03-26
RU2020111709A3 (es) 2022-04-26
SG11202002123XA (en) 2020-04-29
CA3075294A1 (en) 2019-05-02
AR113805A1 (es) 2020-06-10
US20200353022A1 (en) 2020-11-12
CN111278448A (zh) 2020-06-12
JP2021501150A (ja) 2021-01-14
BR112020007494A2 (pt) 2020-11-03
KR20200078483A (ko) 2020-07-01
EP3700544A1 (en) 2020-09-02
WO2019084418A1 (en) 2019-05-02
TWI817958B (zh) 2023-10-11
RU2020111709A (ru) 2021-11-29

Similar Documents

Publication Publication Date Title
MX2019012038A (es) Composiciones que comprenden una combinacion de un anticuerpo anti gen 3 de activacion del linfocito (lag-3), un inhibidor de la trayectoria del receptor de muerte programada 1 (pd-1), y un agente inmunoterapeutico.
ZA202006627B (en) Methods and compositions for treating cancer
MX2023007841A (es) Metodos, composiciones y componentes relacionados con crispr-cpf1 para la inmunoterapia contra el cancer.
MX2021000710A (es) Composiciones que comprenden cepas bacterianas.
MX2020012797A (es) Anticuerpos biespecificos anti-pvrig/anti-tigit y métodos de uso.
MX2020012204A (es) Inhibidores de kras g12c para tratar el cáncer.
EP3947715A4 (en) METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER
MX2019001471A (es) Anticuerpos anti-siglec-7 para el tratamiento del cancer.
PH12017501999A1 (en) K-ras modulators
MX2021007773A (es) Compuestos inhibidores de egfr.
MX2018016038A (es) Compuestos y metodos para modular la funcion del acido ribonucleico (arn).
IL271326A (en) Compositions and methods for enhancing radiotherapy in cancer
EP3518689A4 (en) COMPOSITIONS AND METHODS FOR IMPROVING CANCER RADIATION THERAPY
MX2018008383A (es) Inmunoterapia contra el cáncer mediada por superantígeno mejorada por inmunopotenciador.
PH12017501879A1 (en) Methods for treating cancer
MX2020006297A (es) Variantes de cd19.
EP3892282A4 (en) COMBINATIONS FOR TREATING CANCER
SG11202012435UA (en) Compositions and methods for treating cancer
PH12018501943A1 (en) Pharmaceutical compositions for the treatment of cancer
IL268163A (en) Methods, compositions, and kits for treatment of cancer
MX2018003301A (es) Inhibidores de pcna.
MX2017014436A (es) Compuestos biciclicos.
MX2020003388A (es) Composiciones y metodos para tratar cancer hepatico.
EP3496743A4 (en) COMPOSITIONS AND METHODS FOR THE TREATMENT OF ARGININ DEPLETION CANCER USING IMMUNOONCOLOGY AGENTS
SG11202106295WA (en) Compositions and methods for cancer therapy